Therapeutic antibody company AIMM Therapeutics has collaborated with Italy-based Cosmo Pharmaceuticals to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases, including colon carcinoma.
As part of the agreement, Cosmo Pharmaceuticals, using its proprietary MMX technology will formulate new human monoclonal antibodies generated by AIMM Therapeutics in an extended release form.
AIMM Therapeutics CEO Jan de Vries said, ''We expect that the combination of Cosmo's MMX technology with AIMM's antibodies will allow us to build a unique portfolio of products with a compelling competitive advantage in gastrointestinal disease."
Cosmo Pharmaceuticals chairman and CEO Mauro Ajani said, "Access to AIMM's proprietary high quality antibodies through our partnership will enable us to rapidly advance the oral delivery of diagnostic and therapeutic antibodies into clinical studies."
The financial details of the partnership were not revealed by the companies.
